Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

AB

Aspire Biopharma Holdings, Inc.

$7.69

-0.05 (-0.58%)

Market Cap
9.95 M
EPS
-153.56
P/E Ratio
-
Value Trade
217.17 K
SEC Financials
Q1 2026

  • Dilution Risk

    80%

  • Revenue

    28.35 K

  • R&D Expenses

    296.72 K

  • Operating CF

    -3.04 M

  • Total Assets

    7.12 M

  • Total Liabilities

    3.25 M

  • Equity

    3.87 M

4.3 %
Week
26.32 %
1 Month
36.61 %
3 Month
-82.54 %
6 Month
-99.95 %
5 Year
-99.95 %
All Time
Cash Data
Distressed

  • Cash Position

    5.86 M

  • Monthly Burn

    1.01 M

  • Runway

    3.1 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 15, 2026
Overview
Volume
67.04 K
52 Week Range
3.31 - 1,050.36
% held by Insiders
5.91 %
% held by Institutions
0.98 %
Enterprise Value
4.06 M
Total Shares
1.30 M
Short %
9.7 %
Float Shares
4.51 M
Company Description
HQ: 23150 FASHION DRIVE, SUITE 232...
https://www.aspirebiolabs.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
NDA Submission example
acetylsalicylic acid (aspirin) 162 mg sublingual powder (OTASA) emergency treatment of suspected acute myocardial infarction (heart attack)
NDA
—

Subscribe to access the data.

Small Molecules
Cardiovascular System
acetylsalicylic acid (aspirin) 162 mg sublingual powder (OTASA) emergency treatment of suspected acute myocardial infarction (heart attack)
NDA
—

Subscribe to access the data.

Small Molecules
Cardiovascular System
acetylsalicylic acid (aspirin) 162 mg sublingual powder (OTASA) emergency treatment of suspected acute myocardial infarction (heart attack)
NDA
—

Subscribe to access the data.

Small Molecules
Cardiovascular System
Unlock Upcoming Catalyst data

Catalyst Timeline

Dated clinical, regulatory & corporate events for Aspire Biopharma Holdings, Inc.

39Total events
4Upcoming
12Tier-1 (high impact)
2022 – 2026Coverage

Upcoming catalysts 2

TBD
T1NDA Submission
Subscribe to view catalyst details
TBD
T2Equity Offering
Subscribe to view catalyst details

Event history 2

TBD
◆AcquisitionCorporate
Subscribe to view catalyst details
TBD
◆AcquisitionCorporate
Subscribe to view catalyst details
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
—
Example Drug
Phase 3 data readout
Phase 3
—
–
0%
0%
Unlock Historical Catalyst data
Drug Pipeline Intelligence
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01

The study met its primary endpoint demonstrating statistically significant improvement.

Read More

Phase 3 Study Results Announcement

Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ASBP
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
ASBP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ASBP
Aug 10, 2026
ASBPGeneral
▼ -0.6%today

Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

Aspire Biopharma has successfully acquired Dura Driver Control Systems, a prominent automotive supplier. This acquisition is expected to significantly enhance Aspire's revenue and profitability, while diversifying its business portfolio. The move positions Aspire to capitalize on growing trends in vehicle and mobility control systems. The acquisition is seen as a transformative milestone for the company.

Read more →
-ASBP
Jul 20, 2026
ASBPGeneral
▲ +5.4%on this news· ran to +21% by day 1

Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma’s BUZZ BOMB(TM)

Aspire Biopharma has announced that freestyle motocross legend Jarryd McNeil will be the newest sponsored athlete for their BUZZ BOMB™ brand. This partnership is expected to enhance the brand's presence in action sports and emphasize its commitment to providing fast-acting energy products. The collaboration is aimed at connecting with elite athletes and active consumers globally.

Read more →
-ASBP
Jun 26, 2026
ASBPConferences/Events
▼ -7%on this news

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

The Life Sciences Virtual Investor Forum held on June 24-25, 2026, has made its presentations available for on-demand viewing. Investors can access these presentations 24/7 for a period of 90 days. Additionally, select companies are accepting management meeting requests until June 19.

Read more →
-ASBP
Jun 24, 2026
ASBPGeneral
▲ +6%on this newsshared move

Aspire Biopharma’s BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs

Aspire Biopharma's subsidiary, Buzz Bomb Caffeine Company, has launched its BUZZ BOMB 50mg caffeine stick packs on Amazon. This product aims to cater to active individuals seeking convenience with a waterless, rapid-dissolve caffeine solution. The nationwide distribution signifies a significant step for the company's e-commerce strategy.

Read more →
-ASBP
Jun 23, 2026
ASBPConferences/Events

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

The Life Sciences Virtual Investor Forum is scheduled for June 24th and 25th, 2026. This event will cater to individual and institutional investors, advisors, and analysts. Participants are encouraged to pre-register to enhance their experience and receive updates. The forum aims to facilitate meaningful discussions in the life sciences sector.

Read more →
-ASBP
Jun 17, 2026
ASBPConferences/Events
▼ -5.1%on this newsshared move

Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th

Aspire Biopharma Holdings, Inc. announced its participation in the Life Sciences Investor Forum on June 25, 2026. The event will feature a live presentation and offer opportunities for one-on-one meetings with investors. This engagement highlights the company's commitment to investor relations and growth.

Read more →
-ASBP
Jun 12, 2026
ASBPGeneral
▼ -17.3%on this newsshared move

Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems , a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue Aspire to acquir

Aspire Biopharma announced the signing of a definitive Share Purchase Agreement to acquire Dura Driver Control Systems for $30 million in cash. This acquisition is expected to enhance Aspire's revenue and earnings growth, providing immediate high-volume revenue-generating operations. Dura Driver Control Systems, a leading automotive supplier, delivered over $200 million in revenue in FY2025, and boasts a strong intellectual property portfolio. The transaction is anticipated to close in the third quarter of 2026, subject to customary closing conditions.

Read more →
-ASBP
May 28, 2026
ASBPGeneral
▲ +18.4%on this news· ran to +29% by day 3

Aspire Biopharma Issues Shareholder Letter

Aspire Biopharma Holdings, Inc. has issued a letter to shareholders highlighting its plans for 2026. CEO Kraig Higginson emphasizes the company's commitment to transforming its clinical pipeline into commercial success. The letter reflects a positive outlook for the future, particularly regarding their innovative drug delivery technology.

Read more →
-ASBP
May 27, 2026
ASBPGeneral
▼ -7.9%on this newsshared move

Aspire Biopharma’s BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members

Aspire Biopharma's subsidiary, Buzz Bomb Caffeine Company, has partnered with EoS Fitness to offer its sublingual caffeine stick packs through the gym's affiliate program. This collaboration aims to enhance the fitness experience for millions of EoS members, promoting high-performance lifestyles. The partnership signifies a strategic move to expand Buzz Bomb's market presence.

Read more →
-ASBP
Apr 20, 2026
ASBPGeneral

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition Company secures Commit

Aspire Biopharma has announced the successful closure of the final tranche of a $21 million private placement aimed at financing its acquisition of Dura Control Systems (DCS). Additionally, the company has secured a commitment letter for a new credit facility of up to $22.5 million to facilitate the purchase. The acquisition of DCS, anticipated to enhance Aspire's revenue generation capabilities, aligns with the company's strategy to strengthen its financial position and promote its innovative drug delivery technology. However, the completion of the acquisition is subject to several risks, including regulatory approvals and financial due diligence outcomes.

Read more →
-ASBP
Apr 16, 2026
ASBPGeneral
▼ -44.9%on this news· ran to -64% by day 3shared move

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue ESTERO, FL /

Aspire Biopharma Holdings, Inc. announced a Letter of Intent to acquire Dura Driver Control Systems, a manufacturer focusing on automotive driver control systems. This acquisition, valued at $30 million, is expected to enhance Aspire's position in the biopharma industry by diversifying their operations. Dura Driver is projected to generate more than $200 million in revenue for the fiscal year ended December 31, 2025, supported by its strong management team. However, the deal remains contingent on successful due diligence and final agreement between the parties involved.

Read more →
-ASBP
Mar 3, 2026
ASBPPhases

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Aspire Biopharma has partnered with Microsize to develop a sublingual powder formulation of alprazolam, aiming for faster anxiety relief. This innovative approach seeks to bypass the digestive system for quicker effects, with a Phase 1 clinical trial planned for mid-2026. Alprazolam remains a highly prescribed medication, indicating a strong market opportunity for this new formulation.

Read more →
-ASBP
Feb 20, 2026
ASBPFDA Updates

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Aspire Biopharma has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, ensuring its continued listing on the exchange. The company had previously met the minimum bid price requirement of $1.00 per share. However, it will be monitored for one year to ensure ongoing compliance, with risks of delisting if standards are not met.

Read more →
-ASBP
Feb 17, 2026
ASBPGeneral
▲ +11.2%on this newsshared move

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Aspire Biopharma has filed a provisional patent application for a new sublingual powder formulation of Meclizine, aimed at providing rapid relief from motion sickness and vertigo. This innovative delivery system is designed to bypass traditional oral administration delays, potentially transforming the treatment landscape for vestibular disorders. The global market for Meclizine is expected to grow significantly, highlighting the strategic importance of this development.

Read more →
-ASBP
Feb 13, 2026
ASBPGeneral
▲ +9.2%on this news· ran to +21% by day 1shared move

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Aspire Biopharma has appointed Phillip Balatsos to its Board of Directors, effective February 6, 2026. His extensive experience in financial markets and operational efficiency is expected to support the company's growth strategy. Balatsos will also serve on the Audit and Compensation Committees, contributing to the development of Aspire's patent-pending drug delivery technology.

Read more →
-ASBP
Feb 12, 2026
ASBPFDA Updates

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Aspire Biopharma has filed a provisional patent application for a new sublingual powder formulation of ondansetron, aimed at providing rapid relief from nausea associated with chemotherapy, radiation, or surgery. This innovative delivery system is designed to bypass the gastrointestinal tract, potentially reducing the onset of action from 30 minutes to mere minutes. The global ondansetron market is projected to grow significantly, and Aspire plans to utilize the FDA's 505(b)(2) pathway to expedite development.

Read more →
-ASBP
Feb 11, 2026
ASBPGeneral

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Aspire Biopharma announced a $21 million private placement to strengthen its financial position. The company sold 26,250 shares of Series A Convertible Preferred Stock, with an initial closing generating $11 million. This funding aims to help Aspire comply with Nasdaq's stockholder equity requirements and support its ongoing drug delivery technology development.

Read more →
-ASBP
Feb 10, 2026
ASBPGeneral

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aspire Biopharma has successfully regained compliance with Nasdaq's minimum bid price requirement, achieving a closing bid of $1.00 for 10 consecutive business days. Nasdaq has confirmed that the compliance matter is closed. The company is optimistic about its strategic plans for 2026 and expects to provide further details soon.

Read more →
-ASBP
Jan 29, 2026
ASBPGeneral
▼ -8.2%on this news· ran to +34% by day 1

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Aspire Biopharma has entered into a partnership with Microsize to develop a sublingual aspirin formulation aimed at treating acute myocardial infarction. This collaboration will facilitate the preparation for clinical trials and a New Drug Application submission planned for late 2026. The agreement underscores Aspire's commitment to innovation and product quality in drug delivery technology.

Read more →
-ASBP
Jan 28, 2026
ASBPGeneral

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Aspire Biopharma has filed a provisional patent for a novel sublingual powder formulation of clopidogrel, aiming to enhance bioavailability and minimize gastric side effects associated with traditional tablets. This formulation is part of Aspire's strategy to create sublingual alternatives for existing medications. The company plans to commercialize this through the FDA's 505(b)(2) regulatory pathway.

Read more →
-ASBP
Jan 20, 2026
ASBPGeneral
▼ -9%on this news

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Aspire Biopharma has filed a provisional patent for a novel sublingual formulation of alprazolam, the active ingredient in Xanax, aimed at providing rapid anxiety relief. This new delivery system is designed to enhance bioavailability and reduce onset time from 30 minutes to just minutes. A Phase 1 clinical trial is planned for mid-2026, marking a significant step in addressing patient needs.

Read more →
-ASBP
Jan 15, 2026
ASBPGeneral
▼ -11.6%on this newsshared move

Aspire Biopharma Announces Reverse Stock Split

Aspire Biopharma Holdings, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-40, effective January 16, 2026. This decision, approved by stockholders, aims to meet Nasdaq's minimum bid price requirement. The split will reduce outstanding shares from approximately 158.8 million to about 4.0 million, while maintaining stockholder equity percentages.

Read more →
-ASBP
Dec 3, 2025
ASBPFDA Updates
▼ -10.8%on this news

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma has submitted a Pre-IND meeting request to the FDA for its sublingual aspirin product aimed at treating suspected acute myocardial infarction. The submission marks a significant milestone towards potential FDA approval. The product demonstrated rapid action and superior efficacy in clinical trials, with results showing faster inhibition of platelet aggregation compared to conventional aspirin.

Read more →
-ASBP
Jun 10, 2025
ASBPGeneral

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - with Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - to be its New Chief Executive Officer Michael Howe - who curre

Aspire Biopharma Holdings, Inc. has appointed Michael C. Howe as its new CEO, effective June 10, 2025. Howe, currently an independent board member, has extensive experience with notable brands such as MinuteClinic and Procter & Gamble. He is recognized for his ability to drive significant growth and innovation. His leadership will be vital as Aspire prepares for the launch of its novel pre-workout supplement and advances its clinical trials in the coming years.

Read more →
-ASBP
May 8, 2025
ASBPConferences/Events

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

Aspire Biopharma Holdings, Inc. will present at the Sidoti Virtual Investor Conference on May 21, 2025. CEO Kraig Higginson will lead the presentation at 2:30 PM Eastern. Additionally, the company will host virtual one-on-one meetings with investors on May 21 and 22. A replay of the presentation will be available on their investor relations website.

Read more →
-ASBP
Apr 29, 2025
ASBPPhases

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc. has received Institutional Review Board approval for its Phase I clinical trial of an oral transmucosal fast-acting high-dose aspirin formulation. The trial will evaluate the safety and pharmacokinetics of the formulation in healthy adult volunteers, with enrollment expected to begin shortly. This trial is a crucial step towards potential FDA approval for treating acute myocardial infarction.

Read more →
-ASBP
Apr 14, 2025
ASBPConferences/Events

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Aspire Biopharma Holdings, Inc. will present at the Emerging Growth Conference on April 17, 2025. CEO Kraig Higginson will discuss the company's Phase 1 clinical study of a fast-acting aspirin formulation. This trial aims to optimize drug formulation and inform future FDA submissions for treating acute myocardial infarction.

Read more →
-ASBP
Apr 11, 2025
ASBPGeneral

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc. has begun initial production of its single dose pre-workout supplement, which features a proprietary sublingual delivery technology. The supplement is designed to enhance athletic performance and will be available in multiple flavors. Consumer and safety testing is planned for the second quarter of 2025, with a market launch expected later that year.

Read more →
-ASBP
Apr 9, 2025
ASBPPhases

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc. has initiated a Phase 1 clinical trial for its oral transmucosal fast-acting high-dose aspirin formulation. The trial aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of the product, with patient enrollment expected in April. Initial clinical data is anticipated by the end of Q2 2025, and Aspire plans to request fast track approval from the FDA.

Read more →
-ASBP
Feb 21, 2025
ASBPGeneral
▼ -58.4%on this news· ran to -72% by day 3

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in this Current Report on Form 8-K ("Form 8-K") and, if not defined

Aspire Biopharma Holdings, Inc. (formerly PowerUp Acquisition Corp.) has submitted an unaudited pro forma condensed combined financial report. This document captures the financial position of Aspire and PWUP as if their business combination had been completed as of September 30, 2024. The report includes balance sheets and statements of operations reflecting this merger, providing essential insights into financial aspects and future implications. It also highlights that the Business Combination will be accounted for as a reverse recapitalization under GAAP principles.

Read more →
-ASBP
Feb 20, 2025
ASBPGeneral

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq The closing of the business combination with PowerUp Acquisition Corp. creates Nasdaq-listed biopharmaceutical company dedicated to developing breakthro

Aspire Biopharma Holdings, Inc. has announced its public listing on Nasdaq following a successful business combination with PowerUp Acquisition Corp. The merger, concluded on February 17, 2025, is believed to enhance Aspire's financial capacity and help accelerate the development of its innovative fast-acting aspirin product for cardiology emergencies. The company aims to leverage its novel sublingual delivery technology to offer a range of FDA-approved drugs and nutraceuticals. This step is seen as pivotal for Aspire's growth and strategic partnerships in the biopharmaceutical sector.

Read more →
-ASBP
Sep 3, 2024
ASBPGeneral

Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA-Approved Drugs, Nutraceuticals and Supplements

Aspire Biopharma, Inc. has announced a business combination with PowerUp Acquisition Corp. to create a Nasdaq-listed biopharmaceutical company. The merger, valued at approximately $316 million, aims to leverage Aspire's innovative drug delivery technology and expand its product pipeline. The combined entity is expected to be named Aspire Biopharma Holdings, Inc. and plans to launch a sublingual aspirin product to address cardiology emergencies.

Read more →
-ASBP
Sep 3, 2024
ASBPGeneral

Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and S

Aspire Biopharma, Inc. and PowerUp Acquisition Corp. have announced a definitive agreement for a business combination aimed at creating a newly listed biopharmaceutical company on Nasdaq. The transaction, valuing Aspire at approximately $316 million, is expected to finalize by the end of Q4 2024 or early Q1 2025, subject to stockholder and regulatory approvals. Aspire's unique drug delivery technology aims to improve efficacy and safety for FDA approved drugs, and the combined entity plans to focus on innovative solutions in the market.

Read more →
-ASBP
Jul 31, 2024
ASBPGeneral

Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp.

Aspire Biopharma, Inc. has signed a letter of intent with PowerUp Acquisition Corp. for a potential business combination. This merger aims to create a publicly listed company focused on innovative drug delivery technologies, including a sublingual aspirin product designed for rapid absorption. The transaction is still subject to regulatory approvals and other conditions.

Read more →
-ASBP
May 20, 2024
ASBPGeneral

PowerUp Acquisition Corp. Announces Postponement of Extraordinary General Meeting of Shareholders New York, NY

PowerUp Acquisition Corp. has postponed its extraordinary general meeting of shareholders from May 21, 2024, to May 22, 2024. Shareholders will vote on extending the deadline for the company to complete a business combination from May 23, 2024, to February 17, 2025. The company has also extended the deadline for shareholders to submit their shares for redemption. This delay raises concerns about shareholder confidence and the company's future business prospects.

Read more →
-ASBP
Mar 20, 2024
ASBPGeneral

Aspire Biopharma, Inc. Engages CTM Advisory, Ltd., and Receives Advisory Engagement from Spartan Capital Securities, LLC to Explore NASDAQ Listed Company Merger

Aspire Biopharma, Inc. has engaged CTM Advisory, Ltd. and plans to work with Spartan Capital Securities, LLC to explore merger opportunities with NASDAQ-listed companies. The company aims to leverage its innovative drug delivery technology to enhance market presence and shareholder value. CEO Kraig Higginson expressed optimism about the potential growth and impact of their technology in the biotech sector.

Read more →
-ASBP
Jan 18, 2024
ASBPFDA Updates

Aspire Biopharma, Inc. Signs Pharmaceutical Development Agreement with Glatt Air Techniques, Inc.

Aspire Biopharma, Inc. has announced the organization of its timeline for a 505(b) fast track FDA Trial for its sublingual aspirin product. The company is collaborating with Glatt Air Techniques for the GMP batch run, with a pivotal FDA meeting scheduled for mid-February. This product aims to serve as a therapeutic pain management alternative, potentially impacting heart attack, stroke, and migraine sufferers.

Read more →
-ASBP
Dec 27, 2023
ASBPGeneral

Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp. Tarrytown, NY and New York, NY

Visiox Pharmaceuticals, Inc. has announced a definitive agreement for a business combination with PowerUp Acquisition Corp., which will lead to its listing on the Nasdaq Capital Market. This transaction is anticipated to close in the first quarter of 2024, establishing Visiox Holdings, Inc. with trading symbols VSXP and VSXPW. The company focuses on developing ophthalmic treatments, with a pipeline including therapies for glaucoma and post-surgical inflammation. This move is expected to bolster their capacity to address significant market needs in ophthalmology.

Read more →
-ASBP
Sep 5, 2023
ASBPGeneral

Aspire Biopharma, Inc. Announces Newly Appointed Medical Advisory Board Members

Aspire Biopharma, Inc. has appointed three new members to its Medical Advisory Board, enhancing its expertise in drug delivery technologies. The new advisors include notable professionals from cardiology and orthopedic surgery. The company aims to leverage their experience to advance its innovative drug delivery solutions, which are designed to improve patient care.

Read more →
-ASBP
Apr 11, 2022
ASBPGeneral

PowerUp Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing

PowerUp Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing April 11, 2022 New York, NY, April 7, 2022 - PowerUp Acquisition Corp. (the "Company") (NASDAQ: PWUPU) announced today that, commencing April 11, 2022, holders of t

Read more →
-ASBP
Feb 23, 2022
ASBPGeneral

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors of PowerUp Acquisition Corporation Opinion on the Financial Statement We have audited the accompanying balance sheet of P

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING To the Shareholders and Board of Directors of PowerUp Acquisition Corporation Opinion on the Financial Statement have audited the accompanying balance sheet of PowerUp Acquisition Corp (the "Company") as of February 23, 2022,

Read more →
-ASBP
Feb 17, 2022
ASBPGeneral

PowerUp Acquisition Corp. Announces Pricing of $250 Million Initial Public Offering New York, NY

PowerUp Acquisition Corp. Announces Pricing of $250 Million Initial New York, NY, February 17, 2022 PowerUp Acquisition Corp. (the "Company") announced today that it priced its initial public offering of 25,000,000 units at $10.00 per unit. The units will be listed on the Nasd

Read more →
Competitive Position
How ASBP ranks across every disease it competes in
Competitive Position is a premium feature
See how ASBP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial